Q3 2025 Mineralys Therapeutics Inc Earnings Call Transcript
Key Points
- Mineralys Therapeutics Inc (MLYS) received pre-NDA feedback from the FDA with no surprises, indicating a smooth path towards NDA submission.
- The company's clinical trials, Launch-HTN and Advance-HTN, demonstrated that lorundrostat offers a clinically meaningful and sustained reduction in systolic blood pressure.
- Lorundrostat showed consistent, statistically significant, and clinically meaningful reductions in blood pressure across diverse patient populations, including Black or African-Americans and those with resistant hypertension.
- The Explore-CKD trial showed that lorundrostat was well tolerated and demonstrated a clinically meaningful reduction in systolic blood pressure and urinary albumin creatinine ratio, indicating potential renal protection.
- Mineralys Therapeutics Inc (MLYS) has a strong financial position with $593.6 million in cash, cash equivalents, and investments, sufficient to fund operations into 2028.
- R&D expenses decreased due to the conclusion of the lorundrostat pivotal program, which may indicate a slowdown in new research initiatives.
- G&A expenses increased significantly, primarily due to higher compensation expenses and professional fees, which could impact profitability.
- The net loss for the quarter was $36.9 million, although reduced from the previous year, still indicates ongoing financial challenges.
- There is uncertainty regarding the exact impact of missing data and imputation methods on trial results, which could affect regulatory evaluations.
- The company has not disclosed specific details about partnering discussions, which could be crucial for commercialization and maximizing lorundrostat's market potential.
Greetings, and welcome to Mineralys third-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Dan Ferry. Thank you. You may begin.
Thank you, operator. I would like to welcome everyone joining us today for our third quarter 2025 conference call. Earlier this afternoon, we issued a press release providing our third quarter 2025 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately 1 hour after its completion. After our prepared remarks, we will open the call for Q&A.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could materially could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
